Vertex Pharmaceuticals (VRTX) Preferred Stock Liabilities (2009 - 2010)

Vertex Pharmaceuticals' (VRTX) quarterly Preferred Stock Liabilities came in at $11.2 million in Q3 2010, down 21.89% quarter-over-quarter from $14.3 million in Q2 2010.

Vertex Pharmaceuticals (VRTX) Preferred Stock Liabilities (2009 - 2010) Analysis & Trends

Vertex Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $11.2 million for Q3 2010.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $11.2 million in Q3 2010; TTM through Sep 2010 was $11.2 million, a N/A change from a year earlier, with the FY2009 full-year figure at $10.5 million, changed N/A from the prior year.
  • Preferred Stock Liabilities declined to $11.2 million in Q3 2010 per VRTX's latest filing, from $14.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $14.3 million in Q2 2010 and bottomed at $10.5 million in Q4 2009.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2010 11.17 Mn
Jun 30, 2010 14.30 Mn
Dec 31, 2009 10.45 Mn